Assessment of coagulation with 6% hydroxyethyl starch 130/0.4 in cesarean section by Oh, Chung-Sik et al.
Korean J Anesthesiol 2012 April 62(4): 337-342 
http://dx.doi.org/10.4097/kjae.2012.62.4.337  Clinical Research Article
Background: Third-generation hydroxyethyl starch (HES) solutions have been developed to minimize negative 
effects on hemostasis. In normal pregnancy, the coagulation activity increases, reaching a maximum around term. 
This study examined the effects of hemodilution with HES 130/0.4 (6%) on blood coagulation in parturients in vivo 
and in vitro.
Methods: Forty parturients scheduled for cesarean sections were assigned randomly to receive either 500 or 1,000 
ml of HES 130/0.4 (6%). Rotation thromboelastometry (ROTEM
Ⓡ) measurements were performed before and after 
administering HES 130/0.4 (6%). In addition, blood samples obtained from 20 randomly selected parturients were 
diluted 10% to 40% using HES 130/0.4 (6%), and ROTEM
Ⓡ measurements were performed before and after dilution. 
The changes from baseline and the effects of dilution were analyzed by ROTEM
Ⓡ parameters.
Results: Infusions of 500 or 1,000 ml of HES 130/0.4 (6%) in the parturients altered the clot formation time, α angle, 
and maximal clot firmness, although all remained within normal ranges. HES 130/0.4 (6%) affected in vitro blood 
coagulation in parturients’ blood containing 10, 20, 30, and 40% HES. The clotting time was prolonged at each 
dilution percentage, but remained within the normal range. Other parameters showed an impairment of the 
coagulation system.
Conclusions: Blood coagulation in parturients may be compromised at high dilution ratios of HES 130/0.4 (6%) to 
blood. Nevertheless, the infusion of 1,000 ml of HES 130/0.4 (6%) in normal parturients did not significantly affect 
blood coagulation. (Korean J Anesthesiol 2012; 62: 337-342)
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Introduction
Normal pregnancy is associated with changes in hemostasis, 
including an increase in the concentration of most clotting 
factors (fibrinogen, VII, VIII, X, XII), in particular fibrinogen and 
factor VII are markedly increased [1]. Although anticoa  gulant 
activity decreases, as seen by decreased protein S concentration 
and activated protein C resistance, fibrinolysis is impaired 
[2,3]. These hematologic alterations are probably beneficial in 
limiting blood loss at delivery. 
In patients with severe intravascular fluid deficits prior to the 
arrival of blood for transfusion, colloids should be considered 
as the initial resuscitation fluid. Several colloid solutions are 
generally available. Unlike other synthetic colloids, hydro  xyethyl 
starch (HES) is nonantigenic, and anaphylactoid reactions are 
rare. Although HES has additional negative effects on hemostasis, 
recent new HES solutions, medium molecular weight (130 kd) 
and low molar substitution (0.4), are assumed to have a lower 
effect on coagulation [4]. In normal pregnancy, the coagulation 
activity in maternal blood increases, reaching a maximum around 
term. However, there are only few studies that have investigated 
the effects of diluting parturient blood with HES 130/0.4 (6%) in 
vivo and in vitro, using rotation thromboelastometry (ROTEM
Ⓡ). 
ROTEM
Ⓡ has been developed from standardized thrombela-
stogram. ROTEM
Ⓡ shows more rapid and stable results com-
pared to thromboelastography
Ⓡ (TEG), and suggests proper 
guidelines for the diagnosis of coagulopathy in severe-bleeding 
expected surgeries.
This study compared baseline ROTEM
Ⓡ measurements 
bet  ween two parturient groups according to administration of 
different HES volume and examined the effects of hemodilution 
with HES 130/0.4 (6%) on blood coagulation in parturients in 
vivo and in vitro.
Materials and Methods
Study population
This study was performed after obtaining approval from the 
Institutional Review Board at our center, and informed consent 
was obtained from all participants. We studied forty parturients 
who were scheduled for elective cesarean section and all were 
ASA physical status I-II. Parturients with a history of coagulation 
disorders, preeclampsia, placenta previa, multiple pregnancy, 
hemorrhage, current aspirin use, or heparin therapy were 
excluded from this study. 
Study design
Blood samples were obtained from 40 parturients and 
baseline hemostatic data and ROTEM
Ⓡ parameters were 
measured. Parturient groups were divided in to two groups. 
The first group received HES 500 ml (Group HES 500), using 
two syringes, a 5 ml venous blood sample was obtained from 
the antecubital vein without venous stasis from each volunteer 
before anesthetic induction. The first 3 ml was discarded to 
avoid tissue contamination with tissue thromboplastin and the 
second 2 ml was collected in a tube containing sodium citrate 
(Vacuette
Ⓡ, Greiner Bio-One GmbH, Kremsmünster, Austria). 
After that, ROTEM
Ⓡ analysis was performed. The second group 
(Group HES 1000) received HES 1,000 ml using the same 
methods, and before anesthetic induction, a 2 ml venous blood 
sample was obtained and ROTEM
Ⓡ analysis was performed. In 
addition, blood samples obtained from 20 randomly selected 
parturients were diluted 10, 20, 30, and 40% using HES 130/0.4 
(6%), after which ROTEM
Ⓡ analysis was performed before and 
after dilution. 
In all groups, endotracheal intubation was done after 
induction of anesthesia with 4 mg/kg thiopental sodium and 
1.5 mg/kg succinylcholine, and then 0.05 mg/kg vecuronium 
was injected intravenously. During the surgery, mechanical 
ventilation was maintained using a mixture of 50% oxygen (2 L/
min) with sevoflurane (0.7-1.2 vol%) and nitrous oxide (2 L/
min).
After placental expulsion, 100 μg carbetocin, which is an 
oxytocin agonist, was injected intravenously for providing 
assistance to uterine contractions. In the group HES 500, after 
the operation started and the fetus was removed, 6% Voluven
Ⓡ 
(Fresenius Kabi Korea, Seoul, Korea), which is a medium 
molecular weight HES with a molar substitution of 0.4, was 
administrated in a volume of 500 ml intravenously. In the 
group HES 1000, 6% Voluven
Ⓡ 1,000 ml was administrated 
intravenously. Immediately after administration of Voluven
Ⓡ, 
2 ml venous blood samples were obtained from members of 
all groups in the same way as before anesthetic induced blood 
sampling. Samples were obtained from the peripheral vein, 
which is not the former blood sampling obtained. Following 
that, ROTEM
Ⓡ analysis was performed. The dropping rate of 
HES was to maintain the target hemodynamic range (mean 
arterial blood pressure > 60 mmHg, within 20% of baseline 
heart rate), during anesthesia, and end tidal CO2 concentration 
was maintained at 35-38 mmHg. In the two groups, additional 
300 ml Hartmann’s solution was also given in the light of 
NPO times and intraoperative insensible loss. All patients 
were observed carefully by one anesthesiologist. There were 
no side effects, including anaphylactic reaction, generalized 
edema, or renal dysfunction. All blood samples for the study 
were collected in a tube containing sodium citrate. Samples 
were collected and analysed simultaneously at 37
oC on a 
four-channel ROTEM
Ⓡ with InTEM
Ⓡ, which is an intrinsic 339 www.ekja.org
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coagulation system screening test and activates clot formation 
by means of CaCl2 and partial thromboplastin.
Parameters of ROTEM
Ⓡ
Through the ROTEM
Ⓡ with InTEM
Ⓡ analysis, clotting time 
[CT, r (reaction time) in conventional TEG], clot formation 
time [CFT, k (kinetics) in conventional TEG], α angle [(α slope 
between r and k) in conventional TEG] and maximum clot 
firmness [MCF, MA (maximum amplitude) in conventional 
TEG] were measured. CT is the time until the initiation of 
clotting. The results depended on the concentration of coagu-
lation factors and the presence of inhibitors. CFT is the time 
from the initiation of clotting until amplitude of 20 mm is 
reached, and represents clot kinetics. α-Angle is determined 
by the angle between the center line and tangent to the curve 
through an amplitude of 2 mm, and this represents clot 
strengthening. MCF is the maximum amplitude of thromboela-
stogram, and it represents clot firmness. The known reference 
values are: for CT, 141.5 ± 15.8 sec (range: 100-240); for CFT, 
71.0 ± 18.5 sec (range: 30-110); for α angle, 76.5 ± 3.3
o (range: 
70-83); for MCF, 61.0 ± 5.5 mm (range: 50-72).
Statistics
The data were analysed using the Statistical Package for 
Social Science (SPSS for Windows, ver. 12.0; SPSS Inc, Chicago, 
IL, USA), and expressed as the mean ± SD. Normally distri-
buted data (tested by the Kolmogorov-Smirnov test) were 
analyzed using the Student’s t-test, paired t-test and repeated 
measure analysis of variance, as appropriate. A paired t-test 
was performed to analyse changes from baseline within each 
group. Student’s t-test was performed to compare between the 
two groups. Repeated measure analysis of variance was used 
to compare ROTEM
Ⓡ parameters according to progressive in 
vitro hemodilution. A P value < 0.05 was considered statistically 
significant.
Results
There were no significant differences between the two 
groups in terms of age, height, and weight (Table 1). 
Comparison of ROTEM
Ⓡ analysis in the parturient 
group according to HES administration volume
There were no significant differences in the preoperative 
ROTEM
Ⓡ analysis between group HES 500 and group HES 1000 
(Table 2).
Administration of 500 or 1,000 ml of HES 130/0.4 (6%) in 
the parturients prolonged the CFT and decreased the α angle 
and MCF. Although theses values remained within a normal 
reference range, they were statistically different (Table 2).
Comparison of ROTEM
Ⓡ analysis in the parturient 
group according to hemodilution with HES in vitro
HES 130/0.4 (6%) was affected during in vitro blood coagu-
lation in parturient blood containing 10, 20, 30, and 40% HES. 
The CT and CFT were significantly prolonged. α-Angle and 
MCF were significantly decreased at each dilution percentage 
(Table 3, Fig.1). Although CT was significantly increased 
compare with the earlier dilution, it was the within normal range 
even at 40 dilution percentage. The α angle deviated from the 
normal range at a 10% dilution. CFT deviated from the normal 
Table 1. Demographic and Obstetric Data of the Patients in This 
Study
HES 500 (n = 20) HES 1000 (n = 20)
Age (yr)  
Height (cm)
Weight (kg)
32.4 ± 4.85
159 ± 6.45
66.95 ± 10.96
34.4 ± 2.48
161.7 ± 3.74
71.15 ± 9.94
Values are expressed as mean ± SD or number of patients.
Table 2. Comparison of ROTEM
Ⓡ with InTEM
Ⓡ Data in the HES 500 and HES 1,000 Groups before and after Infusion of HES 500 ml and 1,000 ml, 
Respectively 
HES 500 (n = 20) HES 1000 (n = 20)
Before infusion After infusion P value Before infusion After infusion P value
CT (sec)
CFT (sec)
α angle (
o)
MCF (mm)
141.6 ± 20.1
 78.1 ± 16.3
75.4 ± 2.7
65.5 ± 5.4
 143.4 ± 27.2
  102.7 ± 20.0*
 71.2 ± 3.3*
 61.7 ± 4.0*
0.828
0.001
0.001
0.002
142.8 ± 18.0
 78.8 ± 12.3
73.5 ± 4.2
63.6 ± 4.2
146.3 ± 18.2
 103.0 ± 15.3
†
69.5 ± 4.1
†
60.9 ± 4.3
†
0.546
0.001
0.01
0.02
Values are expressed as mean ± SD or number of patients. HES 500 ml group: comparison of ROTEM
Ⓡ with InTEM
Ⓡ data from blood sampling 
before and after infusion of HES 500 ml, HES 1,000 ml group: Comparison of ROTEM
Ⓡ with InTEM
Ⓡdata from blood sampling before and 
after infusion of HES 1,000 ml, CT: clotting time, CFT: clot formation time, α angle: slope of tangent at 2 mm amplitude, MCF: maximum clot 
firmness. *P value < 0.05 compared with before HES 500 ml infusion. 
†P value < 0.05 compared with before HES 1,000 ml infusion.  340 www.ekja.org
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range at 20, 30, and 40% dilution and MCF deviated from the 
normal range at 40% dilution.
Discussion
Normal pregnancy is associated with changes in all aspects 
of hemostasis. During pregnancy, the coagulation factors VII, 
VIII, IX, X, XII and von Willebrand factors rise significantly, 
accompanied by a pronounced increase in fibrinogen levels, 
which increase up to two times above those of non-pre-
gnant levels, whereas antithrombin III levels decrease [1-3]. 
Anticoagulant concentration and fibrinolytic activity decrease, 
thus causing a state of hypercoagulability to exist compared 
with non-pregnant women. 
In relation to thrombosis, quantitative analysis of coagu-
lation factors such as platelet count, prothrombin time (PT) 
and activated partial thromboplastin time (aPTT) may only 
represent a part of the blood coagulation process. 
Thromboelastography does not show quantitative values 
such as standard coagulation tests, but it allows for the analysis 
of whole blood coagulation mechanisms. It also measures 
the viscoelastic properties of blood as well as coagulation 
factor and platelet activity from a single blood sample [4]. 
Thromboelastography (TEG
Ⓡ) was first described by Hatrert 
(1948) [5], and has continued to evolve for the evaluation 
of coagulation function of whole blood. Using whole blood, 
TEG
Ⓡ measures the viscoelasticity of blood and records 
the graphical representation of the fibrin polymerization 
process. In addition, TEG
Ⓡ provides information including 
the initiation of coagulation, fibrin-platelet interaction, clot 
firmness, and fibrinolysis. However, in specific circumstances, 
coagulation is not initiated by a biochemical agonist, and the 
shortcomings are that it takes a long time to obtain results 
and is susceptible to vibrations [4]. As a modified form of 
conventional thromboelastography, ROTEM
Ⓡ (modified 
rotation thromboelastogram analyzer) has been used recently 
to observe the formation of thrombi, using an optical detector 
Table 3. ROTEM
Ⓡ with InTEM
Ⓡ Data in the Parturient Group before and after in vitro Hemodilution with HES 130/0.4 (6%)
Baseline
(n = 20)
10% dilution
(n = 20)
20% dilution
(n = 20)
30% dilution
(n = 20)
40% dilution
(n = 20)
CT (sec)
CFT (sec)
α angle (
o)
MCF (mm)
141.9 ± 19.3
78.2 ± 14.5
74.2 ± 3.9
64.3 ± 4.7
145.2 ± 12.0*
103.1 ± 12.4*
64.9 ± 2.0*
61.9 ± 2.2*
172.1 ± 9.5*
134.9 ± 16.9*
63.6 ± 5.5*
58.4 ± 4.4* 
181.1 ± 8.4*
157.0 ± 10.6*
58.8 ± 3.5 *
56.1 ± 4.4* 
196.0 ± 8.5*
246.6 ± 24.2*
54.8 ± 3.2*
49.3 ± 3.7*
Values are expressed as mean ± SD. CT: clotting time, CFT: clot formation time, α angle: slop of tangent at 2 mm, amplitude, MCF: maximum 
clot firmness. Baseline: ROTEM
Ⓡ with InTEM
Ⓡ anlaysis data before infusion of HES in the parturient blood. 10% dilution: ROTEM
Ⓡ with 
InTEM
Ⓡ anlaysis data, in vitro, after 10% dilution in the parturient blood with HES (130/0.4). 20% dilution: ROTEM
Ⓡ with InTEM
Ⓡ anlaysis 
data, in vitro, after 20% dilution in the parturient blood with HES (130/0.4). 30% dilution: ROTEM
Ⓡ with InTEM
Ⓡ anlaysis data, in vitro, after 
30% dilution in the parturient blood with HES (130/0.4). 40% dilution: ROTEM
Ⓡ with InTEM
Ⓡ anlaysis data, in vitro, after 40% dilution in the 
parturient blood with HES (130/0.4). *P value < 0.05 compared with before dilution of parturient’s blood.
Fig. 1. In vitro, ROTEM
Ⓡ with InTEM
Ⓡ analysis graph before and after 
hemodilution with HES (130/0.4). The examples of the study result 
of Table 3. The clotting time (CT) and clot formation time (CFT) were 
significantly prolonged where α angle and maximal clot firmness (MCF) 
were significantly decreased at each dilution percentage. α angle 
deviated from the normal range at 10% dilution. CFT deviated from 
the normal range at 20, 30, 40% dilution and MCF deviated from the 
normal range at 40% dilution.341 www.ekja.org
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system, instead of the torsion wire used in TEG
Ⓡ [6]. Therefore, 
ROTEM
Ⓡ leads to fewer errors in the sample, and a more rapid 
measurement (within 30 min). For this reason, ROTEM
Ⓡ is 
increasingly being used in clinical practice. 
This study aimed to compare qualitative coagulation ten-
dency with HES infusion via ROTEM
Ⓡ analysis in healthy 
parturients undergoing a cesarean section. Also, to evaluate 
hemodilutional effects of HES, we compared the effects of 
progressive (10, 20, 30, and 40%) in vitro hemodilution with HES 
using ROTEM
Ⓡ analysis. The background of this study was that 
if we assume a body weight of 60 kg for a parturient, estimated 
total blood volume in the parturient may be 5,400 ml (90 ml/
kg) because of increased blood volume [7]. As a result, 10 % 
hemodilution corresponds roughly to 540 ml HES infusion. 
Volumes of 20, 30, and 40% hemodilution correspond to 1,080, 
1,620, 2,160 ml HES infusion, respectively. 
HES 130/0.4 (6%) is considered a general value, and its 
maximal or safe dosage is 20 ml/kg, yet this is just the manu-
facturer’s guideline, and is not supported by published data 
[8,9]. In addition, even though numerous studies have been 
per  formed to evaluate the effects of HES 130/0.4 (6%) on 
coagulation [10-16], few studies have been conducted to 
evaluate the safety and efficacy of HES 130/0.4 (6%) in vivo and 
in vitro, especially in parturients using ROTEM
Ⓡ analysis [17]. 
HES has a negative effect on blood coagulation according 
to degree of molar substitution and mean molecular weight 
[18]. The third-generation HES 130/0.4, appears to have 
relatively fewer negative effects on hemostasis compared to 
first-generation high mean molecular weight and high molar 
substitution (450/0.7) [11]. However, despite a lower molecular 
weight and molar substitution HES, hemodilution after large 
volume replacement leads to the dilution of red blood cells, 
platelets, and coagulation factors. Also, additional surgical 
bleeding, hypothermia, and inflammatory reactions can cause 
the delay of blood coagulation. Besides dilutional coagulopathy, 
HES decreases fibrinogen concentration, activity of factor VII, 
VIII, IX, and von Willebrand factor levels [19], as well as reduced 
platelet function by coating the platelet surface or inducing 
platelet damage [20].
Butwick and Carvalho [21], have demonstrated that 
statistically significant increases in TEG parameters (r and k 
times) following preloading with 500 ml HES 670/0.75 (6%) in 
pregnant patients prior to spinal anesthesia for elective cesarean 
delivery, although these post-fluid loading TEG parameters 
remained within a normal reference range. In the present in 
vivo study, administration of 500 ml, or higher volumes than 
previous study [21] of up to 1,000 ml of HES 130/0.4 (6%) in 
the parturients altered ROTEM
Ⓡ parameters, prolonged clot 
formation time (CFT) and decreased α angle, and maximal 
clot firmness (MCF). These values remained within a normal 
reference range. Furthermore, in an in vitro study, CT prolonged 
and MCF decreased but also remained within the normal range 
of up to 40 and 30% dilution, respectively. Our results indicate 
that, in parturients, initial fibrin formation and the strength of 
blood clots with clot firmness were not significantly affected by 
the administration of HES 130/0.4 (6%) up to 1,000 ml volume. 
In addition, we can cautiously infer that the reasons behind 
why the coagulation factors and fibrinogen levels increased in 
parturients may be related to this result. Thus, if the amount of 
HES administration is adjusted within the correct range in a 
clinical infusion dose, HES does not have a major influence on 
bleeding in parturients. In the case of surgery of parturients that 
show the hypercoagulable state fundamentally, we expect that 
the permissible limit of HES administration can be larger until a 
normal coagulable state. 
Meanwhile, the α angle and CFT deviated from the normal 
range in vitro at a relatively lower dilution percentage compared 
with CT and MCF, and this shows the administration of 
HES 130/0.4 at 30% dilution can impair fibrin kinetics and 
polymerization in parturient blood. 
However, extrapolation of in vitro data with the data found 
in the clinical setting is difficult, because results from the in 
vitro studies do not necessarily concur with the situation in 
surgery. In our in vivo study, the α angle and CFT remained 
within the normal range even after 1,000 ml infusion of HES, 
which corresponds to roughly 20% dilution in the in vitro study. 
However, these results deviated from the normal range in our 
in vitro study at the same dilution percentage. We assumed 
that this result was related to a neuroendocrine stress response 
and the effect of blood coagulation by vascular endothelial 
cell which occur during surgery. Surgery causes changes 
in hemostasis by neuroendocrine stress, increased platelet 
reactivity and decreases circulation coaugulation inhibitors, 
finally causing a generalized hypercoagulable state [22]. The 
potential effects of these coagulation changes in parturients on 
clinical outcomes remain unclear.
Jamnicki et al. [23], demonstrated the effects of in vitro 
hemodilution (30% and 60%) on blood coagulation in patients 
receiving HES 130/0.4 (6%) and 200/0.5 (6%) solutions using 
TEG
Ⓡ. As a result, r and k increased, and MA and α angle 
decreased progressively with an increasing degree of hemo-
dilution in both HES solution. This finding was in accordance 
with our results. We found that HES 130/0.4 (6%) progressively 
impaired in vitro blood coagulation in parturient blood 
containing 10, 20, 30, and 40% HES. This indirectly showed 
that the administration of HES 130/0.4 (6%) to the parturients 
lead to impairment of coagulation in proportion to the amount 
of HES volume. Particularly, in addition to coagulation factor 
impairment induced by HES administration, massive fluid 
administration leads to dilutional coagulopathy, which is a 342 www.ekja.org
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factor of increasing the blood loss. Thus, in relation to dilutional 
coagulopathy, clinical studies are necessary to fully evaluate 
the hemostatic influence of the large volume HES 130/0.4 
administration in parturients to assess the clinical relevance of 
our findings.
In conclusion, blood coagulation in parturients may be 
compromised at high dilution ratios of medium molecular 
weight, a lower molar substitution HES 130/0.4 (6%) to 
blood. Nevertheless, the infusion of 1000 ml of HES 130/0.4 
(6%) in normal parturients did not significantly affect blood 
coagulation. 
References
1. Miller RD. Miller’s anesthesia. 7th ed. Philadelpia, Elsevier 
Churchill livingstone. 2009, p 2205.
2. Hellgren M. Hemostasis during normal pregnancy and puerperium. 
Semin Thromb Hemost 2003; 29: 125-30.
3. Brenner B. Haemostatic changes in pregnancy. Thromb Res 2004; 
114: 409-14.
4. Whitten CW, Greilich PE. Thromboelastography: past, present, and 
future. Anesthesiology 2000; 92: 1223-5.
5. Hartert H. Blutgerinnungsstudien mit der thrombelastographie, 
einem neuen untersuchungsverfahren . Klin Wochenschr 1948; 26: 
577-83.
6. Ganter MT, Hofer CK. Coagulation monitoring: current techniques 
and clinical use of viscoelastic point-of-care coagulation devices. 
Anesth Analg 2008; 106: 1366-75.
7. Morgan GE. Clinical anesthesiology. 7th ed. New York, McGraw-
Hill. 2006, p 876.
8. Warren BB, Durieux ME. Hydroxyethyl starch: safe or not? Anesth 
Analg 1997; 84: 206-12.
9. Wiedermann CJ. Hydroxyethyl starch 130/0.4: does "modern" mean 
safe? Anesth Analg 2009; 109: 1346-7.
10. Konrad CJ, Markl TJ, Schuepfer GK, Schmeck J, Gerber HR. In vitro 
effects of different medium molecular hydroxyethyl starch solutions 
and lactated Ringer’s solution on coagulation using SONOCLOT. 
Anesth Analg 2000; 90: 274-9.
11. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, 
Haagenaars JA, van Oeveren W, et al. A novel hydroxyethyl starch 
(Voluven) for effective perioperative plasma volume substitution in 
cardiac surgery. Can J Anaesth 2000; 47: 1207-15.
12. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. 
Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), 
causes fewer effects on coagulation in major orthopedic surgery 
than HES 200/0.5. Anesth Analg 2001; 92: 855-62.
13. Franz A, Bräunlich P, Gamsjäger T, Felfernig M, Gustorff B, Kozek-
Langenecker SA. The effects of hydroxyethyl starches of varying 
molecular weights on platelet function. Anesth Analg 2001; 92: 
1402-7.
14. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. The influ-
ence of a new hydroxyethyl starch preperation (6% HES 130/0.4) on 
coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 
2001; 15: 316-21.
15. Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A. The influ-
ence of intravascular volume therapy with a new hydroxyethyl 
starch preparation (6% HES 130/0.4) on coagulationin patients 
undergoing major abdominal surgery. Anesth Analg 2001; 92: 565-
71.
16. Boldt J, Haisch G, Suttner S, Kumle B, Schellhaass A. Effects of a 
new modified, balanced hydroxyethyl starch preparation (Hextend)   
on measures of coagulation. Br J Anaesth 2002; 89: 722-8.
17. Sharma SK, Philip J, Wiley J. Thromboelastographic changes in 
healthy parturients and postpartum women. Anesth Analg 1997; 85: 
94-8.
18. de Jonge E, Levi M. Effects of different plasma substitutes on blood 
coagulation: a comparative review. Crit Care Med 2001; 29: 1261-7.
19. Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, 
et al. Hemostatic changes after crystalloid or colloid fluid admini-
stration during major orthopedic surgery: the role of fibrinogen 
administration. Anesth Analg 2007; 105: 905-17.
20. Boldt J, Suttner S. Plasma substitutes. Minerva Anestesiol 2005; 71: 
741-58.
21. Butwick A, Carvalho B. The effect of colloid and crystalloid 
preloading on thromboelastography prior to Cesarean delivery. 
Can J Anaesth 2007; 54: 190-5.
22. Rosenfeld BA, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt 
P. Hemostatic effects of stress hormone infusion. Anesthesiology 
1994; 81: 1116-26.
23. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn 
DR. Compromised blood coagulation: an in vitro comparison of 
hydroxyethyl starch 130/0.4 and hydroxyethyl starch 200/0.5 using 
thromboelastography. Anesth Analg 1998; 87: 989-93.